Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887934 | 0.82 | PARP1 (0.48) | PARP1MAPTALDH1A1 | |
| SCHEMBL5887856 | 0.81 | PARP1 (0.54) | PARP1 | |
| SCHEMBL7083243 | 0.77 | PARP1 (0.51) | PARP1MAPTHTTKDM4E | |
| SCHEMBL7083771 | 0.75 | PARP1 (0.52) | PARP1MAPTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL7080676 | 0.71 | PARP1 (0.49) | PARP1 | |
| SCHEMBL4185101 | 0.71 | APEX1 (0.55) | ALDH1A1KDM4EMAPK1HSD17B10APEX1 | |
| SCHEMBL6520401 | 0.71 | APEX1 (0.78) | ALDH1A1KDM4EMAPK1HSD17B10APEX1 | |
| SCHEMBL2598457 | 0.68 | MAPT (0.50) | PARP1MAPTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL20245334 | 0.68 | MAPT (0.47) | PARP1MAPT | |
| SCHEMBL7344985 | 0.67 | KDM4E (0.49) | ALDH1A1KDM4EMAPK1HSD17B10APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125995-B2 | Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (PARS) | BAYER AKTIENGESELLSCHAFT (DE) | 2006-10-24 | — | — | US | disclosed |
| US-20050075347-A1 | Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (pars) | BAYER AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075347-A1 | Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (pars) | UNG, UMPS, PARP1 | PARP1 3/4885MAPT 3186/4885ALDH1A1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.